Publications

van der Mijn JC, Awamlh BAl Hussein, Khan AIslam, Posada-Calderon L, Oromendia C, Fainberg J, Alshak M, Elahjji R, Pierce H, Taylor B et al..  2019.  Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.. PLoS One. 14(12):e0226285.

Kauffman EC, Robinson BD, Downes M, Marcinkiewicz K, Vourganti S, Scherr DS, Gudas LJ, Mongan NP.  2013.  Estrogen receptor-β expression and pharmacological targeting in bladder cancer.. Oncol Rep. 30(1):131-8.

Raman JD, Mongan NP, Liu L, Tickoo SK, Nanus DM, Scherr DS, Gudas LJ.  2006.  Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma.. Carcinogenesis. 27(3):499-507.

Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ.  2005.  Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.. Clin Cancer Res. 11(24 Pt 1):8570-6.

Boorjian S, Scherr DS, Mongan NP, Zhuang Y, Nanus DM, Gudas LJ.  2005.  Retinoid receptor mRNA expression profiles in human bladder cancer specimens.. Int J Oncol. 26(4):1041-8.

Boorjian S, Ugras S, Mongan NP, Gudas LJ, You X, Tickoo SK, Scherr DS.  2004.  Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer.. Urology. 64(2):383-8.

Boorjian S, Tickoo SK, Mongan NP, Yu H, Bok D, Rando RR, Nanus DM, Scherr DS, Gudas LJ.  2004.  Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer.. Clin Cancer Res. 10(10):3429-37.